Comparing two treatments for a type of esophageal disease.
Comparative study of dupilumab and fluticasone in management of fibrostenotic Eosinophilic Esophagitis; a pilot and feasibility clinical trial.
This study is looking at how well two different treatments work for people with fibrostenotic Eosinophilic Esophagitis, a condition that makes swallowing tough, by comparing a medication called dupilumab with a steroid called fluticasone to see which one helps more.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Colorado Denver NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project ID | NIH-11103161 on NIH RePORTER |
What this research studies
This research investigates the effectiveness of two different treatments for fibrostenotic Eosinophilic Esophagitis (FS-EoE), a condition that causes difficulty swallowing due to inflammation and narrowing of the esophagus. The trial will compare dupilumab, a biologic medication, with fluticasone, a topical corticosteroid, to determine which is more effective in improving symptoms and esophageal function. Patients will be monitored using a novel measurement technique called EndoFLIP, which assesses changes in esophageal narrowing. The goal is to provide valuable data that can guide future treatment options for patients suffering from this condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with fibrostenotic Eosinophilic Esophagitis, both children and adults, who are experiencing significant swallowing difficulties.
Not a fit: Patients who do not have fibrostenotic Eosinophilic Esophagitis or those with other unrelated esophageal conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with fibrostenotic Eosinophilic Esophagitis, improving their quality of life.
How similar studies have performed: Previous research has shown promising results with biologic treatments for Eosinophilic Esophagitis, indicating that this comparative approach could yield valuable insights.
Where this research is happening
Aurora, UNITED STATES
- University of Colorado Denver — Aurora, United States (Active)
Researchers
- Principal investigator: Menard-Katcher, Calies D — University of Colorado Denver
- Study coordinator: Menard-Katcher, Calies D
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.